Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Saved in:
| Title: | Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. |
|---|---|
| Authors: | Janssen JJWM; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, loc. VUmc, Amsterdam, The Netherlands. j.janssen@amsterdamumc.nl., Löwenberg B; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Manz M; USZ Zürich, Zürich, Switzerland.; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands., Biemond BJ; Department of Hematology, Amsterdam University Medical Centers, loc. AMC, Amsterdam, The Netherlands., Westerweel PE; Albert Schweitzer Hospital, Dordrecht, The Netherlands., Klein SK; Department of Hematology, University Medical Center, Groningen, The Netherlands., Fehr M; Kantonsspital St. Gallen, St. Gallen, Switzerland., Sinnige HAM; Jeroen Bosch Hospital, Den Bosch, The Netherlands., Efthymiou A; HFR, Fribourg, Switzerland., Legdeur MCJC; Medisch Spectrum Twente, Enschede, The Netherlands., Pabst T; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; Department of Medical Oncology, University Hospital Inselspital and University of Bern, Bern, Switzerland., Gregor M; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; KSL, Luzern, Switzerland., van der Poel MWM; Dept. of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Deeren D; AZ Delta, Roeselare, Belgium., Tick LW; Maxima Medical Center, Eindhoven, The Netherlands., Jongen-Lavrencic M; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Obbergh F; Hospital Saint Paul Jolimont, Haine, Belgium., Boersma RS; Amphia Hospital, Breda, The Netherlands., de Weerdt O; Antonius Hospital, Nieuwegein, The Netherlands., Chalandon Y; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; Division of Hematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland., Heim D; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; University Hospital, Basel, Switzerland., Spertini O; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland., van Sluis G; Isala Clinics, Zwolle, The Netherlands., Graux C; Mont Godinne, Yvoir, Belgium., Stüssi G; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; IOSI, Belinzona, Switzerland., van Norden Y; Hovon Data Center, Erasmus Medical Center, Rotterdam, The Netherlands., Ossenkoppele GJ; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, loc. VUmc, Amsterdam, The Netherlands. |
| Source: | Leukemia [Leukemia] 2022 Sep; Vol. 36 (9), pp. 2189-2195. Date of Electronic Publication: 2022 Jul 22. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35869267 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Janssen+JJWM%22">Janssen JJWM</searchLink>; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, loc. VUmc, Amsterdam, The Netherlands. j.janssen@amsterdamumc.nl.<br /><searchLink fieldCode="AU" term="%22Löwenberg+B%22">Löwenberg B</searchLink>; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Manz+M%22">Manz M</searchLink>; USZ Zürich, Zürich, Switzerland.; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Biemond+BJ%22">Biemond BJ</searchLink>; Department of Hematology, Amsterdam University Medical Centers, loc. AMC, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Westerweel+PE%22">Westerweel PE</searchLink>; Albert Schweitzer Hospital, Dordrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Klein+SK%22">Klein SK</searchLink>; Department of Hematology, University Medical Center, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Fehr+M%22">Fehr M</searchLink>; Kantonsspital St. Gallen, St. Gallen, Switzerland.<br /><searchLink fieldCode="AU" term="%22Sinnige+HAM%22">Sinnige HAM</searchLink>; Jeroen Bosch Hospital, Den Bosch, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Efthymiou+A%22">Efthymiou A</searchLink>; HFR, Fribourg, Switzerland.<br /><searchLink fieldCode="AU" term="%22Legdeur+MCJC%22">Legdeur MCJC</searchLink>; Medisch Spectrum Twente, Enschede, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Pabst+T%22">Pabst T</searchLink>; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; Department of Medical Oncology, University Hospital Inselspital and University of Bern, Bern, Switzerland.<br /><searchLink fieldCode="AU" term="%22Gregor+M%22">Gregor M</searchLink>; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; KSL, Luzern, Switzerland.<br /><searchLink fieldCode="AU" term="%22van+der+Poel+MWM%22">van der Poel MWM</searchLink>; Dept. of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Deeren+D%22">Deeren D</searchLink>; AZ Delta, Roeselare, Belgium.<br /><searchLink fieldCode="AU" term="%22Tick+LW%22">Tick LW</searchLink>; Maxima Medical Center, Eindhoven, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Jongen-Lavrencic+M%22">Jongen-Lavrencic M</searchLink>; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Obbergh+F%22">van Obbergh F</searchLink>; Hospital Saint Paul Jolimont, Haine, Belgium.<br /><searchLink fieldCode="AU" term="%22Boersma+RS%22">Boersma RS</searchLink>; Amphia Hospital, Breda, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Weerdt+O%22">de Weerdt O</searchLink>; Antonius Hospital, Nieuwegein, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Chalandon+Y%22">Chalandon Y</searchLink>; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; Division of Hematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.<br /><searchLink fieldCode="AU" term="%22Heim+D%22">Heim D</searchLink>; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; University Hospital, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Spertini+O%22">Spertini O</searchLink>; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22van+Sluis+G%22">van Sluis G</searchLink>; Isala Clinics, Zwolle, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Graux+C%22">Graux C</searchLink>; Mont Godinne, Yvoir, Belgium.<br /><searchLink fieldCode="AU" term="%22Stüssi+G%22">Stüssi G</searchLink>; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; IOSI, Belinzona, Switzerland.<br /><searchLink fieldCode="AU" term="%22van+Norden+Y%22">van Norden Y</searchLink>; Hovon Data Center, Erasmus Medical Center, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Ossenkoppele+GJ%22">Ossenkoppele GJ</searchLink>; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, loc. VUmc, Amsterdam, The Netherlands. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228704895%22">Leukemia</searchLink> [Leukemia] 2022 Sep; Vol. 36 (9), pp. 2189-2195. <i>Date of Electronic Publication: </i>2022 Jul 22. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%2C+Specialist+Journals%22">Nature Publishing Group, Specialist Journals </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8704895 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1476-5551 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2208876924%22">08876924 </searchLink><i>NLM ISO Abbreviation: </i>Leukemia <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35869267 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41375-022-01657-3 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2189 Titles: – TitleFull: Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Janssen JJWM – PersonEntity: Name: NameFull: Löwenberg B – PersonEntity: Name: NameFull: Manz M – PersonEntity: Name: NameFull: Biemond BJ – PersonEntity: Name: NameFull: Westerweel PE – PersonEntity: Name: NameFull: Klein SK – PersonEntity: Name: NameFull: Fehr M – PersonEntity: Name: NameFull: Sinnige HAM – PersonEntity: Name: NameFull: Efthymiou A – PersonEntity: Name: NameFull: Legdeur MCJC – PersonEntity: Name: NameFull: Pabst T – PersonEntity: Name: NameFull: Gregor M – PersonEntity: Name: NameFull: van der Poel MWM – PersonEntity: Name: NameFull: Deeren D – PersonEntity: Name: NameFull: Tick LW – PersonEntity: Name: NameFull: Jongen-Lavrencic M – PersonEntity: Name: NameFull: van Obbergh F – PersonEntity: Name: NameFull: Boersma RS – PersonEntity: Name: NameFull: de Weerdt O – PersonEntity: Name: NameFull: Chalandon Y – PersonEntity: Name: NameFull: Heim D – PersonEntity: Name: NameFull: Spertini O – PersonEntity: Name: NameFull: van Sluis G – PersonEntity: Name: NameFull: Graux C – PersonEntity: Name: NameFull: Stüssi G – PersonEntity: Name: NameFull: van Norden Y – PersonEntity: Name: NameFull: Ossenkoppele GJ IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: 2022 Sep Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1476-5551 Numbering: – Type: volume Value: 36 – Type: issue Value: 9 Titles: – TitleFull: Leukemia Type: main |
| ResultId | 1 |
